Table 2.
The lncRNAs that regulate EZH2.
| lncRNA | Cancer | Effect |
|---|---|---|
| lncRNA sponges upstream miRNA of EZH2 | ||
| TUG1 | Pancreatic carcinoma | TUG1 competitively sponges miR-382 to regulate EZH2 and promote tumor progression.129 |
| NEAT1 | Endometrial cancer | NEAT1 acts as a competitive endogenous RNA of miR-144–3p, leading to EZH2 up-regulation and promoting cell proliferation and invasion.21 |
| MALAT1 | Colorectal cancer | MALAT1 promotes EZH2 expression and the development of colorectal cancer as a competitive endogenous RNA by sponging miR-363–3p.130 |
| ADAMTS9-AS2 | Tongue squamous cell carcinoma | ADAMTS9-AS2 promotes tongue squamous cell carcinoma proliferation and metastasis by sponging miR-600, enhancing EZH2 enhancer expression.131 |
| SPRY4-IT1 | Bladder cancer | SPRY4-IT1 acts as miR-101–3p sponge to positively regulate EZH2 expression, thus promoting bladder cancer pathogenesis.132 |
| LINC00662 | Oral squamous cell carcinoma | LINC00662 directly targets miR-144–3p to up-regulate EZH2 and accelerate oral squamous cell carcinoma progress.133 |
| DLGAP1-AS1 | Glioma | DLGAP1-AS1 promotes glioma progression by regulating EZH2 expression through sponging miR-1297.134 |
| EZH2 is recruited by lncRNA | ||
| SNHG8 | Cervical carcinoma | SNHG8 recruited EZH2 to down-regulate RECK expression, leading to the aggravation of human papillomavirus-induced cervical carcinoma.25 |
| CASC9 | Non-small cell lung cancer | CASC9 promotes gefitinib resistance by recruiting EZH2 to inhibit the expression of dual specificity phosphatase 1 epigenetically.135 |
| LINC00152 | Esophageal cancer | LINC00152 promotes the resistance of esophageal cancer cells to oxaliplatin and epithelial–mesenchymal transition by recruiting EZH2.22 |
| LINC01559 | Gastric cancer | LINC01559 recruits EZH2 to repress PTEN.23 |
| FOXP4-AS1 | Gastric cancer | FOXP4-AS1 combines with EZH2/lysine-specific demethylase 1 to form a carcinogenic complex, accelerating gastric cancer cell proliferation, migration, and invasion.136 |
| HOTAIR | Nasopharyngeal carcinoma | HOTAIR promotes nasopharyngeal carcinoma cell progression by recruiting EZH2.137 |
| ZEB2-AS1 | Non-small cell lung cancer | ZEB2-AS1 aggravates the malignant progression of non-small cell lung cancer by recruiting EZH2 to negatively regulate PTEN.138 |
| CASC9 | Esophageal squamous cell carcinoma | CASC9 promotes esophageal squamous cell carcinoma cell growth by recruiting EZH2 and negatively regulating programmed cell death 4 expression.139 |
| LINC00673 | Papillary thyroid carcinoma | LINC00673 inhibits p53 expression by combining with EZH2 and DNA methyltransferase 1, promoting papillary thyroid carcinoma cell proliferation and invasion.140 |
| FOXC2-AS1 | Melanoma | FOXC2-AS1 inhibits p15 transcription via recruiting EZH2 to stimulate the cell proliferation of melanoma.141 |
| EZH2 is stabilized by lncRNA | ||
| FAM83C-AS1 | Colorectal cancer | FAM83C-AS1 combines with ZRANB1 to promote EZH2 deubiquitination, stabilizing EZH2 protein expression.26 |
EZH2, enhancer of zeste homolog 2; TUG1, taurine upregulated gene 1; PTEN, phosphatase and tensin homolog; NEAT1,nuclear enriched abundant transcript 1; MALAT1, metastasis associated lung adenocarcinoma transcript 1; ADAMTS9-AS2, ADAMTS9 antisense RNA 2; SPRY4-IT1, SPRY4 intronic transcript 1; DLGAP1-AS1, DLGAP1 antisense RNA 1; CASC9, cancer susceptibility candidate 9; FOXP4-AS1, Forkhead box P4 antisense RNA 1; HOTAIR, HOX antisense intergenic RNA; ZEB2-AS1, Zinc finger E-box binding homeobox 2 (ZEB2) antisense RNA 1; FOXC2-AS1, Forkhead box protein C2 (FOXC2) antisense RNA 1; FAM83C-AS1, FAM83C antisense RNA 1; ZRANB1, zinc finger RANBP2-type containing 1.